You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202301 - 202310 of 207699 results
  1. Biomarker Matrix for Genotoxicity Mode of Action

    SBC: Litron Laboratories Ltd            Topic: NIEHS

    DESCRIPTION (provided by applicant): It is well recognized that current batteries of genetic toxicology assays exhibit relatively high sensitivity, meaning they effectively identify genotoxic carcinogens. However, a critical deficiency with current approaches exists-namely, the specificity of the in vitro mammalian cell genotoxicity tests is low, as they yield a high incidenc of positive results t ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. CometChip: Development of a high throughput DNA damage assay in hepatocytes

    SBC: INTEGRATED LABORATORY SYSTEMS, LLC            Topic: NIEHS

    DESCRIPTION (provided by applicant): Thousands of new industrial chemicals are produced each year. Knowledge about the potential carcinogenicity of these compounds is therefore critical to public health. It is well-established that DNA damage can lead to the mutations that cause cancer. Therefore, being able to screen chemicals for their potential to damage DNA offers an effective strategy for imp ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Genetics of Drug Induced Cardiotoxicity

    SBC: PREDICTIVE BIOLOGY            Topic: NIEHS

    DESCRIPTION (provided by applicant): We are interested in the genetic basis of drug induced cardiotoxicity, and how these genetic factors may underlie serious adverse drug reactions that affect a small but significant fraction of individuals, therapeutic circumstances, o both. We will conduct genomewide screens for factors affecting cardiomyocyte contractile deficit or arrhythmia caused by anthrac ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Single Therapy for Wet AMD and Geographic Atrophy

    SBC: Novelmed Therapeutics Inc            Topic: NEI

    DESCRIPTION (provided by applicant): Approximately 85% of the total age-related macular degeneration (AMD) patients have the Dry form. Geographic atrophy (GA) is the advanced form of Dry AMD and is caused by the degeneration of the retinal epithelial cells. While GA is less common than Wet AMD, it is responsible for 10-20% of legal blindness in the US. There is currently no FDA approved treatment ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Intrasurgical Optical Coherence Tomography

    SBC: BIOPTIGEN, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Each year, over 20 million ophthalmic surgeries are performed worldwide. Indications for ophthalmic surgery include potentially blinding diseases, such as cataracts, diabetic retinopathy, macular disease, and retinal detachment. Surgeons performing these delicate procedures are challenged by the translucent nature of tissues in the eye, making it nearly impossi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Migrate enzyme modeling technology from development site to experimental research

    SBC: Stewart, James            Topic: NIGMS

    OCR issue PUBLIC HEALTH RELEVANCE Project Narrative The task of designing new pharmaceuticals can be aided by a computer-assisted model of enzyme mechanism that would be easy to use. A program to do this, MOPAC2012, already exists, but currently it is only being used by expert computational chemists. The objective is to modify the MOPAC2012 program and its documentation to make it suitable for u ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an iPSC-derived human hepatocyte platform for drug development.

    SBC: HemoShear Therapeutics, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Human inducible pluripotent stem cells (iPSCs) proliferate readily and can be terminally differentiated into hepatocytes, which potentially makes them an attractive, cost-effective resource compared to primary human hepatocytes. Moreover, the ability to standardize a platform to a single human donor, or donor(s) who may include known genetic drug metabolism pol ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Ion Channel Screening Using Photoswitches

    SBC: PHOTOSWITCH BIOSCIENCES, INC.            Topic: NIGMS

    Ion channels are membrane proteins that allow the selective movement of charged molecules through cellular membranes. Many disease states, such as cystic fibrosis, muscular dystrophies, hypertension, and cardiac arrhythmias are caused by ion channel pathologies. Ion channels have been identified by the drug discovery industry as excellent targets for therapeutic intervention but because of the tec ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Statistical Mechanics with Quantum Potentials: Application to Host-Gues

    SBC: VERACHEM LLC            Topic: NIGMS

    Project Summary Host molecules, such as cyclodextrins and cucurbiturils, can 'capture' smaller molecules and affect their physical and chemical behavior. The stronger the host molecule holds onto, i.e. binds, its smaller 'guest' the larger the effect can be. Host molecules themselves can also be chemically altered (i.e. derivatized), which can change how strongly they bind gues ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Particle display: a new paradigm in high throughput discovery of ultra-high perfo

    SBC: APTITUDE MEDICAL SYSTEMS INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Nucleic acid aptamers have shown great promise as the synthetic alternative to monoclonal antibodies in therapeutics, diagnostics, and RandD tools. Key advantages of aptamers comparing to antibodies include applicability to non-immunogenic targets, chemical and thermal stability, low production cost, and no batch-to-batch variation. Nevertheless, the potential ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government